Felomune CVR (Canada)

Manufacturer: Pfizer

Feline Rhinotracheitis-calici Vaccine

Modified Live Virus

For intranasal use in cats only

Product Description

Felomune CVR for the intranasal vaccination of healthy cats as an aid in preventing feline rhinotracheitis (FVR) caused by feline herpesvirus-1 and feline respiratory disease caused by feline calicivirus (FCV). Felomune CVR contains attenuated strains of feline rhinotracheitis virus and feline calicivirus propagated in an established feline cell line and freeze-dried to preserve stability.

Disease Description

FVR and FCV infections are considered the two most important forms of feline respiratory disease.¹

FVR, caused by feline herpesvirus-1, is highly contagious, spreading both by horizontal (including aerosol) and vertical transmission from queen to kitten. It accounts for approximately 40-45% of feline respiratory infections.² First signs of FVR are sneezing, fever, conjunctivitis, rhinitis, and salivation. An initial serous nasal and ocular discharge which rapidly becomes mucopurulent is typical of the disease. Ulcerative keratitis or glossitis may also occur. As FVR progresses, anorexia, depression, tracheitis, and bronchitis may be observed. Abortion or fetal resorption may occur. The prognosis is guarded if cats remain severely infected for more than 1 week. A carrier state lasting for years with periods of latency alternating with episodes of viral shedding is common. Although few adult cats die from FVR, death rate among affected kittens can range from 50-60%.

FCV infection is believed to account for another 40-45% of feline respiratory infections, and dual FCV-FVR infections are not uncommon.³ FCV infects oral mucous membranes as well as the respiratory tract. Buccal, nasal, and lingual ulcers are characteristic. Other clinical signs of the infection are similar to FVR: anorexia, depression, fever, salivation, and nasal discharge. A carrier state with persistent shedding occurs. FCV most severely affects kittens and debilitated cats, but overall death loss is generally low.

Safety And Efficacy

Felomune CVR was evaluated for safety and efficacy in conventional and specific-pathogen-free cats. Clinical signs of disease or other adverse side effects attributable to vaccination were not observed in any test animals, including pregnant, susceptible cats, which delivered live, healthy litters.

Tests of serologic response to vaccination with Felomune CVR indicated that no interference existed between the vaccine fractions. Even kittens vaccinated as early as 2 weeks of age developed protective FVR and FCV serum neutralization titers at 3 weeks postvaccination.

In challenge-of-immunity tests, all cats vaccinated intranasally with Felomune CVR remained clinically normal after challenge with virulent FCV or FVR virus, In contrast, all nonvaccinated control cats showed signs of disease after challenge.¹

Directions

1. General Directions: Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Shake well. Using sterile dropper, inoculate nasal passages with entire volume of vaccine. Alternatively, 1 drop of vaccine may be placed in each eye and the remainder placed into nasal passages. Administer vaccine with 30 minutes after rehydration.

2. Primary Vaccination: Healthy cats 12 weeks of age or older should receive one 0.5 mL dose. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.

3. Revaccination: Annual revaccination with a single dose is recommended.

Warning

Transient sneezing may be observed 4 to 7 days after vaccination. Oral lesions may be observed postvaccinally, but typically heal without incident. Vaccination of cats incubating or harboring latent infections may result in more pronounced upper respiratory signs, ocular irritation, or febrile response.

Precautions

1. Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

2. Use entire contents immediately after rehydration.

3. Burn container and all unused contents.

4. Contains gentamicin as preservative.

5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

6. This product has been shown to efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

References

1. Davis EV, Beckenhauer WH: Studies on the safety and efficacy of an intranasal feline rhinotracheitis-calici virus vaccine. VM/SAC 71:1405-1410, 1976.

2. The Merck Veterinary Manual, 5th Ed., Otto H. Siegmund, ed. Rahway, Merck and Company, p. 324, 1979.

3. MacLachlan NJ, Burgess GW: Feline viral respiratory tract infection. JAVMA 174:1345, 1979.

Technical inquiries should be directed to Pfizer Animal Health Technical Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only

U.S. Veterinary License No. 189

Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc., NY, NY 10017

003

75-4350-22

^® Registered trademark of Pfizer Products Inc; Pfizer Canada Inc., licensee

Presentation

Available in 25-1 dose vials of vaccine with 25-0.5 mL vials of diluent.

Nac No.

11980530